The protective effects of hyperoxic pre-treatment in human-derived adipose tissue mesenchymal stem cells against in vitro oxidative stress and a rat model of renal ischaemia-reperfusion.
Shahram Ahmadi SomaghianNaser PajouhiOmid DezfoulianAfshin PirniaAyat KaeidiBahram RasoulianPublished in: Archives of physiology and biochemistry (2023)
Objective: Improvement of cell survival is essential for achieving better clinical outcomes in stem cell therapy. We investigated the effects of hyperoxic pre-treatment (HP) on the viability of human adipose stromal stem cells (ASCs). Materials and Methods: MTT and Western blot tests were used to assess cell viability and the expression of apoptosis-related proteins, respectively. For the in-vivo trial, the rats were subjected to renal ischaemia-reperfusion (IR). Results: The results showed that HP could significantly increase the viability of ASCs and decrease apoptotic markers (Bax/BCL-2 ratio and Caspase-3) compared with control cells. There were some additional effects with regard to the improvement of renal structure and function in the animal model. However, the difference between the treated and non-treated transplanted ASCs failed to reach significance. Conclusion: These results suggested that HP could increase the survival of ASCs against oxidative stress-induced damages in the in-vitro condition, but this strategy was not highly effective in renal IR.
Keyphrases
- cell therapy
- induced apoptosis
- oxidative stress
- stem cells
- adipose tissue
- mesenchymal stem cells
- endothelial cells
- cell death
- cell cycle arrest
- endoplasmic reticulum stress
- acute myocardial infarction
- insulin resistance
- bone marrow
- type diabetes
- poor prognosis
- heart failure
- metabolic syndrome
- induced pluripotent stem cells
- coronary artery disease
- combination therapy
- acute ischemic stroke
- pluripotent stem cells
- south africa
- randomized controlled trial
- study protocol
- brain injury
- high fat diet
- signaling pathway
- newly diagnosed
- replacement therapy
- atrial fibrillation
- diabetic rats
- phase iii
- anti inflammatory
- open label